242 related articles for article (PubMed ID: 35357886)
1. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.
Routhu NK; Gangadhara S; Lai L; Davis-Gardner ME; Floyd K; Shiferaw A; Bartsch YC; Fischinger S; Khoury G; Rahman SA; Stampfer SD; Schäfer A; Jean SM; Wallace C; Stammen RL; Wood J; Joyce C; Nagy T; Parsons MS; Gralinski L; Kozlowski PA; Alter G; Suthar MS; Amara RR
Sci Immunol; 2022 Jun; 7(72):eabo0226. PubMed ID: 35357886
[TBL] [Abstract][Full Text] [Related]
2. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
3. V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques.
Styles TM; Gangadhara S; Reddy PBJ; Sahoo A; Shiferaw A; Welbourn S; Kozlowski PA; Derdeyn CA; Velu V; Amara RR
Front Immunol; 2022; 13():914969. PubMed ID: 35935987
[TBL] [Abstract][Full Text] [Related]
4. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
Routhu NK; Cheedarla N; Gangadhara S; Bollimpelli VS; Boddapati AK; Shiferaw A; Rahman SA; Sahoo A; Edara VV; Lai L; Floyd K; Wang S; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Upadhyay AA; Pellegrini K; Montefiori D; Shi PY; Menachery VD; Alter G; Vanderford TH; Bosinger SE; Suthar MS; Amara RR
Immunity; 2021 Mar; 54(3):542-556.e9. PubMed ID: 33631118
[TBL] [Abstract][Full Text] [Related]
5. Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.
Bošnjak B; Odak I; Barros-Martins J; Sandrock I; Hammerschmidt SI; Permanyer M; Patzer GE; Greorgiev H; Gutierrez Jauregui R; Tscherne A; Schwarz JH; Kalodimou G; Ssebyatika G; Ciurkiewicz M; Willenzon S; Bubke A; Ristenpart J; Ritter C; Tuchel T; Meyer Zu Natrup C; Shin DL; Clever S; Limpinsel L; Baumgärtner W; Krey T; Volz A; Sutter G; Förster R
Front Immunol; 2021; 12():772240. PubMed ID: 34858430
[TBL] [Abstract][Full Text] [Related]
6. Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2.
Mooij P; García-Arriaza J; Pérez P; Lázaro-Frías A; Verstrepen BE; Böszörményi KP; Mortier D; Fagrouch Z; Kiemenyi-Kayere G; Niphuis H; Acar RF; Meijer L; Stammes MA; Kondova I; Verschoor EJ; GeurtsvanKessel CH; de Bruin E; Sikkema RS; Luczkowiak J; Delgado R; Montenegro D; Puentes E; Rodríguez E; Bogers WMJM; Koopman G; Esteban M
Front Immunol; 2022; 13():845887. PubMed ID: 35371043
[TBL] [Abstract][Full Text] [Related]
7. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.
Pérez P; Albericio G; Astorgano D; Flores S; Sánchez-Corzo C; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2023; 14():1264323. PubMed ID: 38155964
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
García-Arriaza J; Garaigorta U; Pérez P; Lázaro-Frías A; Zamora C; Gastaminza P; Del Fresno C; Casasnovas JM; Sorzano CÓS; Sancho D; Esteban M
J Virol; 2021 Mar; 95(7):. PubMed ID: 33414159
[TBL] [Abstract][Full Text] [Related]
9. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
[TBL] [Abstract][Full Text] [Related]
10. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2021; 12():824728. PubMed ID: 35154086
[TBL] [Abstract][Full Text] [Related]
11. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
12. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():845969. PubMed ID: 35371064
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
Perdiguero B; Marcos-Villar L; López-Bravo M; Sánchez-Cordón PJ; Zamora C; Valverde JR; Sorzano CÓS; Sin L; Álvarez E; Ramos M; Del Val M; Esteban M; Gómez CE
Front Immunol; 2023; 14():1160065. PubMed ID: 37404819
[TBL] [Abstract][Full Text] [Related]
14. Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.
Kalodimou G; Jany S; Freudenstein A; Schwarz JH; Limpinsel L; Rohde C; Kupke A; Becker S; Volz A; Tscherne A; Sutter G
Viruses; 2023 May; 15(5):. PubMed ID: 37243266
[TBL] [Abstract][Full Text] [Related]
15. Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection.
Gómez-Carballa A; Albericio G; Montoto-Louzao J; Pérez P; Astorgano D; Rivero-Calle I; Martinón-Torres F; Esteban M; Salas A; García-Arriaza J
Antiviral Res; 2023 Dec; 220():105760. PubMed ID: 37992765
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination.
Tscherne A; Schwarz JH; Rohde C; Kupke A; Kalodimou G; Limpinsel L; Okba NMA; Bošnjak B; Sandrock I; Odak I; Halwe S; Sauerhering L; Brosinski K; Liangliang N; Duell E; Jany S; Freudenstein A; Schmidt J; Werner A; Gellhorn Serra M; Klüver M; Guggemos W; Seilmaier M; Wendtner CM; Förster R; Haagmans BL; Becker S; Sutter G; Volz A
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34162739
[TBL] [Abstract][Full Text] [Related]
17. Study of immunogenicity and efficacy against Omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates.
Pal R; Ferrari MG; Honda-Okubo Y; Wattay L; Caple J; Navarrete J; Andersen H; Petrovsky N
Vaccine; 2024 Feb; 42(5):1122-1135. PubMed ID: 38262808
[TBL] [Abstract][Full Text] [Related]
18. Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.
Meyer Zu Natrup C; Tscherne A; Dahlke C; Ciurkiewicz M; Shin DL; Fathi A; Rohde C; Kalodimou G; Halwe S; Limpinsel L; Schwarz JH; Klug M; Esen M; Schneiderhan-Marra N; Dulovic A; Kupke A; Brosinski K; Clever S; Schünemann LM; Beythien G; Armando F; Mayer L; Weskamm ML; Jany S; Freudenstein A; Tuchel T; Baumgärtner W; Kremsner P; Fendel R; Addo MM; Becker S; Sutter G; Volz A
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36301637
[TBL] [Abstract][Full Text] [Related]
19. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
[TBL] [Abstract][Full Text] [Related]
20. Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.
Rice A; Verma M; Voigt E; Battisti P; Beaver S; Reed S; Dinkins K; Mody S; Zakin L; Tanaka S; Morimoto B; Olson CA; Gabitzsch E; Safrit JT; Spilman P; Casper C; Soon-Shiong P
Front Immunol; 2022; 13():910136. PubMed ID: 35911728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
